To the full analysis
RHÖN-KLINIKUM stock: growth
RHK.DERHÖN-KLINIKUM reported $2.14B in revenue for fiscal 2025, up 21.3% on the prior year, up 7.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
0%
per year from 2006 to 2025, per share 2.5%
Earnings (Annual rate)
−5.7%
per year from 2006 to 2025, per share −3.4%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 7.3% | 5.7% | 0.0% |
| Revenue per share | 7.3% | 6.5% | 2.5% |
| Earnings | 88.4% | −8.7% | −5.7% |
| Earnings per share | 88.8% | −7.9% | −3.4% |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $2.14B | $116.57M | $261.07M |
| 2007 | $2.24B | $117.78M | $201.67M |
| 2008 | $2.36B | $135.9M | −$90.09M |
| 2009 | $2.57B | $145.88M | −$81.33M |
| 2010 | $2.83B | $160.75M | −$113.14M |
| 2011 | $2.91B | $172.99M | −$19.95M |
| 2012 | $3.17B | $99.38M | −$59.84M |
| 2013 | $3.34B | $96.01M | $49.98M |
| 2014 | $1.67B | $1.36B | −$49.53M |
| 2015 | $1.23B | $94.61M | −$6.87M |
| 2016 | $1.3B | $62.53M | −$4.88M |
| 2017 | $1.34B | $38.95M | −$39.34M |
| 2018 | $1.37B | $54.29M | −$126.21M |
| 2019 | $1.44B | $47.96M | −$74.46M |
| 2020 | $1.51B | $1.61M | $18.06M |
| 2021 | $1.55B | $31.35M | $21.83M |
| 2022 | $1.6B | $27.86M | −$18.73M |
| 2023 | $1.92B | $42.9M | $51.19M |
| 2024 | $1.77B | $48.04M | $63.38M |
| 2025 | $2.14B | $38.2M | −$38.34M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 12 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.